Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDG PET Should Stay In New Tech APC, Reassignment Premature – Comments

This article was originally published in The Gray Sheet

Executive Summary

FDG positron emission tomography should continue to be reimbursed under new technology APC 174 for one to two years under the hospital OPPS system, according to the National Electrical Manufacturers Association and AdvaMed

You may also be interested in...



FDG PET Procedures Will Retain 2002 Payment Rate Under OPPS Final Rule

CMS' decision to continue to pay for FDG positron emission tomography in new technology APC 714 under the hospital outpatient prospective payment system (OPPS) 2003 final rule is in line with comments submitted by the National Electrical Manufacturers Association and AdvaMed

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel